Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Alkermes has named Blair Jackson the company’s new chief operating officer. Jackson will continue in his role of senior vice president of corporate planning.
Alligator Bioscience has found its newest chief medical officer in Christina Reimer, former senior medical director at Ferring Pharmaceuticals.
Alpine Immune Sciences
Pamela Holland, former vice president of cancer biology at Surface Oncology, has joined Alpine Immune Sciences as senior vice president of research.
Fred Aslan takes the helm of Artiva Biotherapeutics as its newest president and CEO. Aslan joins the company from Vividion Therapeutics, where he served as president and chief business officer.
Graham Lumsden has been named president and CEO of Biomarck Pharmaceuticals. Lumsden previously served as CEO of Motif Bio.
Camurus has appointed Andrew McLean vice president of corporate development and senior counsel. Previously, McLean was general counsel, company secretary and chief compliance officer at Kyowa Kirin International.
James Kupiec has been named chief clinical development officer of Cassava Sciences. Prior to this appointment, Kupiec served as vice president and global clinical leader for Parkinson’s disease and clinical head at Pfizer.
Celldex Therapeutics has named Freddy Jimenez the company’s newest senior vice president and general counsel. Most recently, Jimenez was the vice president of law and compliance at Celldex.
David Richards, former chief business officer of Clarametyx Biosciences, has been appointed CEO of the company.
Jason LePree has been named vice president of scientific affairs for Elite Pharmaceuticals. LePree was most recently the associate director of pharmaceutical sciences at Ferring Pharmaceuticals.
Manuel Zafra has been named EMD Serono’s managing director for Canada. Zafra was previously the general manager and managing director for Merck Hungary.
Enanta Pharmaceuticals has appointed John DeVincenzo to the role of vice president of translational virology. DeVincenzo was most recently a pediatric infectious disease specialist and medical doctor at Le Bonheur Children’s Hospital.
Enzon Pharmaceuticals’ chief financial officer Richard Feinstein has been named CEO of the company, which will become effective following Andrew Rackear’s retirement effective Feb. 26.
Martin Brenner has been named iBio’s newest chief scientific officer. Brenner comes to iBio from Pfenex, where he also served as chief scientific officer.
Fabio Benedetti has been named chief strategy officer of ImmunityBio. Previously, Benedetti was chief medical officer for Apollomics.
Inhibikase Therapeutics has partnered with Clintrex Research, naming C. Warren Olanow the company’s interim chief medical officer as part of the process. Olanow is the current CEO of CLINTREX.
Mary Jane Geiger has been named chief medical officer of MBX Biosciences. Geiger was previously the vice president of drug development services at ICON.
David Marek has been appointed CEO of Myovant Sciences. Marek formerly served as chief commercial officer at Axsome Therapeutics.
Nektar Therapeutics has named Brian Kotzin as interim chief medical officer and head of development. Kotzin was previously the vice president of global clinical development at Amgen.
Clinical-stage biotech company NexImmune has named Jerome Zeldis executive vice president of R&D. Most recently, Zeldis was the chief medical officer at Celgene. NexImmune has also appointed Jeffrey Weber, current deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, to the role of chief scientific adviser.
Clare Grace, former vice president of site and patient access at Syneos Health, has been named chief patient officer of Parexel.
Aida Habtezion is taking a leave of absence from Stanford University to assume the position of Pfizer’s chief medical officer.
Pharma Two B
Sheila Oren has been named CEO of Pharma Two B. Oren was formerly a biopharma consultant at Soren Medical Consulting.
Paris-based biopharmaceutical company Pharmaleads has promoted Tanja Ouimet from director of clinical development to chief operating officer. Pharmaleads has also promoted Hervé Poras from director of preclinical operations to chief scientific officer.
Gregory Cosgrove has been appointed vice president of clinical development of Pliant Therapeutics’ idiopathic pulmonary fibrosis clinical development program. In his most recent role, Cosgrove served as the chief medical officer of the Pulmonary Fibrosis Foundation.
Qpex Biopharma has appointed Paul Westberg to be its chief business officer. Westberg joins the company from Versartis, where he served as chief business officer.
Ramona Doyle has been named Recursion’s new chief medical officer. Doyle formerly was medical director at Gilead Sciences, Genentech, Blade Therapeutics and Roche, as well as CEO of telehealth nonprofit the MAVEN Project.
Revive Therapeutics has brought on John Fahy as a scientific and clinical adviser. Fahy will continue to serve as a professor of medicine at the University of California San Francisco.
Ke Liu has joined Sana Biotechnology as the company’s head of regulatory affairs and strategy. Previously, Liu was the associate director for cell and gene therapy at the FDA’s Oncology Center of Excellence.
Taysha Gene Therapies
Taysha Gene Therapies has named Kimberly Lee the company’s senior vice president of corporate communications and investor relations. Lee previously served as head of corporate strategy and investor relations at Lexicon Pharmaceuticals. Taysha also appointed Greg Gara, former construction and commission leader at AveXis Libertyville, to the role of senior vice president of manufacturing.
Frank Neumann has been appointed chief medical officer of Verastem Oncology. Neumann most recently served as vice president and head of oncology clinical research and clinical research development at bluebird bio.
Marianne Mancini, former vice president of clinical operations for Viking Therapeutics, has been named chief operating officer of the company.
Virometix has filled a vacancy in its management team with the appointment of Lilli Stergiou to the position of chief scientific officer (CSO). Previously, Stergiou was CSO at Redbiotec, where she headed the HSV-2 therapeutic vaccine program.